Evidence map›Paper›PMID 40689993›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

[

Gokce Belge Bilgin, Cem Bilgin, Brian J Burkett, Matthew P Thorpe, Ann T Packard, Fatma Fidanli, Daniel S Childs, Miguel Muniz, Jacob J Orme, J Fernando Quevedo and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gokce Belge BilginDepartment of Radiology, Mayo Clinic, Rochester, MN, USA. belgebilgin.gokce@mayo.edu.ORCID 0000-0001-8258-1774
Cem BilginDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Brian J BurkettDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Matthew P ThorpeDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Ann T PackardDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Fatma FidanliDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Daniel S ChildsDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Miguel MunizDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Jacob J OrmeDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
J Fernando QuevedoDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Sani H KizilbashDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Eugene D KwonDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.
Geoffrey B JohnsonDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Derek R JohnsonDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Oliver SartorDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Ayse Tuba KendiDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCentral nervous system (CNS) metastases in prostate cancer are rare but pose a significant treatment challenge and are linked to poor prognosis. Data on the outcomes of this specific patient subgroup treated with radioligand therapy (RLT) remain scarce. In this study, we aim to leverage real-world clinical data to evaluate the outcomes of RLT with [

methodsClinical and imaging data of patients who received their initial dose of [

resultsA total of 589 patients underwent RLT with [

conclusionsOur study suggests that patients with CNS metastases, whether diagnosed before or after therapy, exhibited a poor prognosis, with a median survival of 4.5 months after initiation of RLT. Although a complete/near-complete radiologic response in the CNS lesions was observed in 25% of the patients, only two patients were able to complete more than three cycles of therapy. Given the small sample size, larger multicenter studies are needed to validate these findings.

Indexed as

Brain NeoplasmsDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedProstate-Specific AntigenRadioisotopesRetrospective StudiesTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenRadioisotopesCNS metastasisLu PSMAmCRPCRLTTheranostic

Identifiers

PMID40689993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.